Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beta Bionics, Inc. - Common Stock (NQ:BBNX)

18.63 -0.35 (-1.84%)
Streaming Delayed Price Updated: 10:44 AM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beta Bionics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
The Insider Report: The Bears Have Been Poked – Will They Fall Back Asleep? ↗
 
Via Benzinga
News headline image
Beta Bionics Announces Participation at Upcoming Investor Conferences
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
Beta Bionics (BBNX) Q3 2025 Earnings Transcript ↗
Beta Bionics (BBNX) Q3 2025 Earnings Transcript 
Via The Motley Fool
Topics Earnings Supply Chain
News headline image
Earnings Scheduled For October 28, 2025 ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 6 Analysts Discuss Beta Bionics Stock ↗
 
Via Benzinga
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 6, 2025 ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
As the regular session of the US market on Tuesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
News headline image
Beta Bionics Inc (NASDAQ:BBNX) Tops Q3 2025 Revenue Estimates and Raises Full-Year Guidance ↗
Beta Bionics (BBNX) beat Q3 2025 revenue estimates and raised its full-year guidance. The medical device company reported strong user growth and a narrower-than-expected loss. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Beta Bionics Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Demystifying Beta Bionics: Insights From 5 Analyst Reviews ↗
 
Via Benzinga
News headline image
Beta Bionics to Announce Third Quarter 2025 Financial Results on October 28, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Forecasting The Future: 4 Analyst Projections For Beta Bionics ↗
 
Via Benzinga
News headline image
Beta Bionics Announces Participation at Upcoming Investor Conferences
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics (BBNX) Q2 Revenue Soars 54% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Beta Bionics BBNX Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Beta Bionics Inc (NASDAQ:BBNX) Surpasses Q2 2025 Estimates and Raises Full-Year Guidance ↗
Beta Bionics (BBNX) beats Q2 2025 revenue and EPS estimates, raises full-year guidance. Shares surge 5.7% as iLet Bionic Pancreas and new insulin pump drive growth. 
Via Chartmill
News headline image
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Sonnet BioTherapeutics Drops 5% Intraday, Rebounds 14% After Hours Amid Delisting Concerns ↗
Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN) fell 5.54% on Thursday to close at $3.92, before rebounding 14.29% in after-hours trading to $4.48, amid concerns of a potential NASDAQ delisting. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Beta Bionics to Announce Second Quarter 2025 Financial Results on July 29, 2025
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges ↗
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
News headline image
Beta Bionics Stock Gains After Mixed Analyst Coverage; Wolfe Bullish, Goldman Neutral ↗
Wolfe Research initiated coverage with an ‘Outperform’ rating and a $20 target, while Goldman Sachs started at ‘Neutral’ with a $16 target, citing balanced growth prospects and valuation. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Beta Bionics Reports First Quarter 2025 Financial Results and Raises Annual Guidance for Full Year 2025
From Beta Bionics, Inc.
Via GlobeNewswire
News headline image
Beta Bionics to Present at the Bank of America Securities Health Care Conference
From Beta Bionics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.